Leerink Partners Begins Coverage on Zura Bio (NASDAQ:ZURA)

Leerink Partners initiated coverage on shares of Zura Bio (NASDAQ:ZURA - Free Report) in a report issued on Monday morning, Marketbeat reports. The firm issued an outperform rating and a $15.00 target price on the stock.

Other research analysts have also issued reports about the company. Piper Sandler reiterated an "overweight" rating and issued a $26.00 price objective on shares of Zura Bio in a research report on Thursday, September 19th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zura Bio in a report on Friday, October 18th. Finally, HC Wainwright reissued a "neutral" rating and set a $5.00 price objective on shares of Zura Bio in a report on Monday, October 21st. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $16.75.

Zura Bio Stock Down 0.2 %

ZURA traded down $0.01 during midday trading on Monday, reaching $4.37. 261,635 shares of the company's stock were exchanged, compared to its average volume of 324,420. The business has a 50-day simple moving average of $4.16 and a two-hundred day simple moving average of $4.08. Zura Bio has a one year low of $2.00 and a one year high of $6.35.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Equities analysts predict that Zura Bio will post -0.47 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Someit Sidhu sold 51,728 shares of the stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the sale, the director now owns 2,085,418 shares of the company's stock, valued at approximately $8,070,567.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 22.10% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Palumbo Wealth Management LLC acquired a new position in shares of Zura Bio in the 3rd quarter valued at approximately $156,000. SG Americas Securities LLC bought a new position in shares of Zura Bio in the 3rd quarter valued at $62,000. Point72 Asset Management L.P. acquired a new position in shares of Zura Bio during the 2nd quarter worth $8,446,000. Forefront Analytics LLC lifted its position in shares of Zura Bio by 22.1% during the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company's stock worth $145,000 after buying an additional 7,531 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new stake in Zura Bio in the second quarter valued at about $43,000. 61.14% of the stock is owned by institutional investors and hedge funds.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.